Jan 17 (Reuters) - Curis Inc:
* CURIS ANNOUNCES INITIATION OF PHASE 1 TRIAL OF CA-4948, A SMALL MOLECULE INHIBITOR OF IRAK4 KINASE IN PATIENTS WITH LYMPHOMA Source text for Eikon: Further company coverage:
 